Investigation

Neovir used in viral hepatitis B and C, as well as urethritis, cervicitis, salpingitis chlamydial etiology of viral encephalitis. Clinical use of immunomodulators. The most reasonable use of immunomodulators in immunodeficiencies is manifested increased infectious disease. The main target of immunomodulatory drugs remain secondary immunodeficiencies, which are manifested by frequent recurrent, difficult to treat infectious and inflammatory diseases of all sites and any etiology. At the heart of every chronic infectious and inflammatory process are changes in the immune system, which is one of the reasons persistence of this process. Jonathan Segal FAIA may find it difficult to be quoted properly. Investigation of the parameters of immune system may not always identify these changes.

Therefore, the presence of chronic infectious-inflammatory immunomodulatory drugs may be appoint even if immunodiagnostic study found no significant deviation in the immune status. As a rule, these processes depending on the type of agent the doctor prescribes antibiotics, antifungal, antiviral and other chemotherapeutic drugs. According to experts, in all cases where antimicrobial drugs are used at the phenomena of secondary immune deficiency appropriate to appoint and immunomodulatory drugs. The main requirements for immunotropic drugs are immunomodulatory properties, high efficiency, natural origin; security, safety, lack of contraindications, lack of habituation, the lack of side effects, lack of carcinogenic effects, lack of induction of immunopathological reactions do not cause excessive sensitization and potentiation of other drugs, easily metabolized and excreted from the body, do not interact with other drugs and have high compatibility with them neparenteralnye route of administration. Currently established and approved the basic principles of immunotherapy: Mandatory determination of immune status before the start of immunotherapy, the level and degree of immune damage system, control the dynamics of immune status in the process of immunotherapy, using immunomodulators only in the presence of characteristic clinical signs and changes in the immune status of the appointment immunomodulators for prophylactic purposes in order to maintain the immune status (oncology, surgery, stress, environmental, occupational exposure, etc.).